Starling Oncology, Inc. (DFPH) Net margin 2020–2025
Starling Oncology, Inc. (DFPH) net profit margin by fiscal year — reported net income divided by reported revenue.
-12.1%FY2025 · since FY2020: -7.6% → -12.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -12.1% | +4.4 pp |
| FY2024 | -16.4% | +9.2 pp |
| FY2023 | -25.6% | -25.7 pp |
| FY2022 | 0.1% | +5.4 pp |
| FY2021 | -5.4% | +2.3 pp |
| FY2020 | -7.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More DFPH financial trends
DFPH RevenueDFPH Net incomeDFPH Gross profitDFPH Gross marginDFPH Operating incomeDFPH Operating marginDFPH Operating cash flowDFPH Free cash flowDFPH Capital expendituresDFPH Return on equityDFPH Stock buybacksDFPH Dividends paidDFPH Total assetsDFPH Total liabilitiesDFPH Shareholders’ equityDFPH overview →